Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Adaptimmune Therapeutics plc is a biotechnology business based in the US. Adaptimmune Therapeutics shares (ADAP) are listed on the NASDAQ and all prices are listed in US Dollars. Adaptimmune Therapeutics employs 462 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$5.21|
|52-week range||$3.37 - $7.34|
|50-day moving average||$5.45|
|200-day moving average||$4.72|
|Wall St. target price||$9.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.96|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||-4.40%|
|1 month (2021-09-21)||-5.27%|
|3 months (2021-07-23)||43.92%|
|6 months (2021-04-23)||-4.05%|
|1 year (2020-10-23)||8.54%|
|2 years (2019-10-24)||482.77%|
|3 years (2018-10-24)||6.485|
|5 years (2016-10-24)||6.11%|
Valuing Adaptimmune Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Adaptimmune Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Adaptimmune Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.11. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Adaptimmune Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||$6.2 million|
|Gross profit TTM||$-87,610,000|
|Return on assets TTM||-20.87%|
|Return on equity TTM||-43.43%|
|Market capitalisation||$813.2 million|
TTM: trailing 12 months
There are currently 3.4 million Adaptimmune Therapeutics shares held short by investors – that's known as Adaptimmune Therapeutics's "short interest". This figure is 44.9% down from 6.1 million last month.
There are a few different ways that this level of interest in shorting Adaptimmune Therapeutics shares can be evaluated.
Adaptimmune Therapeutics's "short interest ratio" (SIR) is the quantity of Adaptimmune Therapeutics shares currently shorted divided by the average quantity of Adaptimmune Therapeutics shares traded daily (recently around 4.0 million). Adaptimmune Therapeutics's SIR currently stands at 0.83. In other words for every 100,000 Adaptimmune Therapeutics shares traded daily on the market, roughly 830 shares are currently held short.
However Adaptimmune Therapeutics's short interest can also be evaluated against the total number of Adaptimmune Therapeutics shares, or, against the total number of tradable Adaptimmune Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adaptimmune Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Adaptimmune Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0263% of the tradable shares (for every 100,000 tradable Adaptimmune Therapeutics shares, roughly 26 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Adaptimmune Therapeutics.
Find out more about how you can short Adaptimmune Therapeutics stock.
We're not expecting Adaptimmune Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Adaptimmune Therapeutics's shares have ranged in value from as little as $3.37 up to $7.34. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adaptimmune Therapeutics's is 2.1243. This would suggest that Adaptimmune Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc. , Alpine Immune Sciences, Inc. , and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.